Skip to main content
. 2014 Nov 2;41(4):900–908. doi: 10.1093/schbul/sbu151

Fig. 1.

Fig. 1.

Participant flow through study. *Three rasagiline participants withdrew prior to receiving study medication and 2 withdrew before first scheduled symptom outcome assessment. Therefore, 26 rasagiline participants are available for symptom efficacy analyses and 28 rasagiline participants are available for safety analyses.